Does molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identify new molecular candidate lesions?
The genomic alteration affecting the candidate gene CSMD1 could be important in the development of desmoid tumors.
At clinically relevant plasma concentrations, interactions of SSZ with RFC provide a biochemical rationale for 2 important clinical observations: 1) the onset of (sub)clinical folate deficiency during SSZ treatment, and 2) the lack of additivity/synergism of the combination of SSZ and MTX when these disease-modifying antirheumatic drugs are administered simultaneously. Thus, when considering use of these drugs in combination therapies, the present results provide a rationale both for the use of folate supplementation and for spacing administration of these drugs over time.